Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - April 20, 2026 109 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMN24 IsKia study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR 12 myths about sun safety debunked July 31, 2023 FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof... March 23, 2026 Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases August 26, 2019 Targeting Inflammation Emerges as a Strategy for Treating Cancer August 19, 2022 Load more HOT NEWS Happy 29th Birthday OncoLink! Washington Farmers Harvest Crops For Neighbor With Stage Four Cancer What to Know About Using Activated Charcoal During Cancer Amivantamab Plus Lazertinib Shows Superior Efficacy to Osimertinib in First-Line Treatment...
